Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 8, 2025International Journal of Innovative Technologies in Social ScienceOpen Access

Treatment of Minimal Change Disease in Adults: Current Practice and Future Directions – A Narrative Literature Review

View Full Paper
Ask AI
Bookmark
Share

Authors

CLCezary LubasJKJoanna KłosowskaPŚPiotr Świerczek

Discussion

Loading...

Member takes

Overview

This review highlights glucocorticoids and rituximab for treating nephrotic syndrome in adults, suggesting targeted therapies may improve quality of life.

Key Points

  • Glucocorticoids achieve remission in about 90% of adults with minimal change disease, and relapses affect more than half.
  • Rituximab has shown significant efficacy in managing steroid-dependent cases, indicating a need for alternative treatments.
  • Immunomodulatory therapies targeting B and T cells are in early-phase studies, showing potential for improved outcomes.
  • Future treatment protocols should focus on minimizing adverse effects and optimizing therapy based on individualized responses.

Cite This Study

Lubas et al. (2025) studied this question.

synapsesocial.com/papers/690e8b75a5b062d7a4e73978https://doi.org/10.31435/ijitss.3(47).2025.3979
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1When Minimal Becomes Massive: A Case Report of Childhood-Onset Minimal Change Disease Marching to End Stage Renal Disease Despite Modern Immunotherapy2026
  2. 2Anti-nephrin antibodies in minimal change disease: Case report series2025
  3. 3Anti-CD20 therapies and anti-nephrin autoantibodies in IgA nephropathy with minimal change disease2026
  4. 4Management Strategy for Non‐Responsive and Refractory Celiac Disease in Adults2025
  5. 5Diabetic nephropathy with minimal change disease: a case report2025